Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today ...
Chromatography Online

Highlights from the 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2025)

The 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2025), was held from June 15–19, 2025, in Bruges, Belgium. This “Column Watch” installment ...

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology platformEVX-04 is a therapeutic cancer vaccine candidate ...